Updates
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tyche Industries has informed the stock exchanges that Brazil's health regulatory agency, ANVISA, successfully completed a Good Manufacturing Practice (GMP) inspection at its Kakinada manufacturing facility during the first week of September 2025. ANVISA is the Brazilian equivalent of the US FDA and its GMP clearance certifies that the facility meets Brazil's pharmaceutical quality and manufacturing standards. This approval is a key regulatory milestone required before the company can supply pharmaceutical products to the Brazilian market. Tyche Industries is a Hyderabad-based pharmaceutical company with manufacturing operations in Kakinada. No specific order or revenue figure has been disclosed in this filing.
Positive for shareholders — ANVISA GMP approval removes a key regulatory barrier and opens the door to the large Brazilian pharmaceutical market, which could support future export-driven revenue growth. Near-term stock impact may be limited as no orders or revenue guidance have been disclosed alongside this approval.